Page 27 - 09 EMA
P. 27
ndication
clinical symptoms in adult patients with renal insufficiency not
yet undergoing dialysis.
Treatment of anaemia and reduction of transfusion requirements in
adult patients receiving chemotherapy for solid tumours, malignant
ymphoma or multiple myeloma, and at risk of transfusion as assessed
by the patient's general status (e.g. cardiovascular status, pre-existing
anaemia at the start of chemotherapy).
Retacrit can be used to increase the yield of autologous blood from
patients in a predonation programme. Its use in this indication must be
balanced against the reported risk of thromboembolic events. Treatment
hould only be given to patients with moderate anaemia (no iron
deficiency), if blood-saving procedures are not available or insufficient
when the scheduled major elective surgery requires a large volume of
blood (four or more units of blood for females orfive or more units for
males).
Retacrit can be used to reduce exposure to allogeneic blood transfusions
n adult non-iron-deficient patients prior to major elective orthopaedic
urgery, having a high perceived risk for transfusion complications. Use
hould be restricted to patients with moderate anaemia (e.g. Hb 10-13
g/dl) who do not have an autologous predonation programme available
and with expected moderate blood loss (900 to 1800 ml).
Treatment of symptomatic anaemia associated with chronic renal failure
CRF) in adult and paediatric patients:
treatment of anaemia associated withCRF in adult and
paediatric patients on haemodialysis and adult patients on
peritoneal dialysis (see section 4.4);
treatment of severe anaemia of renal origin accompanied by
clinical symptoms in adult patients with renal insufficiency not
yet undergoing dialysis (see section 4.4);
treatment of anaemia and reduction of transfusion
requirements in adult patients receiving chemotherapy for solid
- 14 -
clinical symptoms in adult patients with renal insufficiency not
yet undergoing dialysis.
Treatment of anaemia and reduction of transfusion requirements in
adult patients receiving chemotherapy for solid tumours, malignant
ymphoma or multiple myeloma, and at risk of transfusion as assessed
by the patient's general status (e.g. cardiovascular status, pre-existing
anaemia at the start of chemotherapy).
Retacrit can be used to increase the yield of autologous blood from
patients in a predonation programme. Its use in this indication must be
balanced against the reported risk of thromboembolic events. Treatment
hould only be given to patients with moderate anaemia (no iron
deficiency), if blood-saving procedures are not available or insufficient
when the scheduled major elective surgery requires a large volume of
blood (four or more units of blood for females orfive or more units for
males).
Retacrit can be used to reduce exposure to allogeneic blood transfusions
n adult non-iron-deficient patients prior to major elective orthopaedic
urgery, having a high perceived risk for transfusion complications. Use
hould be restricted to patients with moderate anaemia (e.g. Hb 10-13
g/dl) who do not have an autologous predonation programme available
and with expected moderate blood loss (900 to 1800 ml).
Treatment of symptomatic anaemia associated with chronic renal failure
CRF) in adult and paediatric patients:
treatment of anaemia associated withCRF in adult and
paediatric patients on haemodialysis and adult patients on
peritoneal dialysis (see section 4.4);
treatment of severe anaemia of renal origin accompanied by
clinical symptoms in adult patients with renal insufficiency not
yet undergoing dialysis (see section 4.4);
treatment of anaemia and reduction of transfusion
requirements in adult patients receiving chemotherapy for solid
- 14 -
